Diligence memo · auto-generated · as of July 2, 2026
STAQ Pharma, Inc.
STAQ Pharma, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
STAQ Pharma, Inc. operates in Pharmaceuticals, based in DENVER.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
STAQ Pharma, Inc. has raised $65M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $30M on 2020-12-21.
Most recent recorded round closed around 2024-09-04.
Valuation (modeled)modeled
Provath models STAQ Pharma, Inc. at approximately $74M (range $24M–$129M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.57× the median modeled value of Series B Pharmaceuticals companies in 2022–2024 (51 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 22 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round stepped up 1.1× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 85% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 49% of those peers.
Closest niche peers: MedAvail Holdings, Inc., Revalesio Corp, Kinaset Therapeutics, Inc., Venatorx Pharmaceuticals, Inc., Cxl Ophthalmics, Inc..
Peoplefiled
16 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.